Nadia Tornieporth
Trustee
Nadia Tornieporth is a physician with extensive leadership experience and expertise in vaccine research and development. She works as an independent clinical consultant, advising both nonprofit and for-profit organizations in vaccinology. Nadia has served as an advisor to prominent organizations such as Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the Coalition of Epidemic Preparedness Innovations (CEPI), the European and Developing Countries Clinical Trials Partnership (EDCTP), the European Forum for Good Clinical Practice (EFGCP), GlaxoSmithKline, Janssen, the Novo Nordisk Foundation, Quantoom, USAID, the Wellcome Trust, and the World Health Organization, among others. She also contributes to several vaccine development programs as a senior advisor and member of various advisory boards, including Independent Data Monitoring Committees.
Previously, Dr. Tornieporth served as a professor of clinical research and pharmacovigilance at the University of Applied Sciences and Arts in Hanover, Germany. Before that, she led global clinical research and development teams at Sanofi Pasteur and GlaxoSmithKline Biologicals.
Over the course of her career, Dr. Tornieporth has played a key role in the successful licensure of over 20 vaccines. She holds clinical patents for malaria and dengue vaccines and has co-authored more than 65 peer-reviewed publications in the fields of infectious diseases, tropical medicine, and vaccine development. Dr. Tornieporth’s work has taken her to more than 40 countries, and she is fluent in English, German, Dutch, and French.
We make vaccines more accessible, enable innovation and expand immunization across the globe.